The ESMO-MCBS Scorecards allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.
High-risk stage II or stage III colon cancerNCCTG 874651
Gastrointestinal Cancers
Colon Cancer
-
NCCTG 874651
A
PRELIMINARY SCORE
DFS
ADJUSTMENTS
FINAL SCORE
F1
A
5-FU (fluorouracil)
Folinic acid
Surgery alone
Patients with resectable Dukes B and C (AJCC/UICC Stage II and Stage III) colon carcinomaGIVIO-SITAC 01
Gastrointestinal Cancers
Colon Cancer
-
GIVIO-SITAC 01
A
PRELIMINARY SCORE
DFS
ADJUSTMENTS
FINAL SCORE
F1
A
5-FU/LV (fluorouracil + leucovorin) or 5-FU/LEV (fluorouracil + levamisole)
-
Surgery alone (Meta-analysis)
Patients with stage II and III colon cancer (ITT and age stratified including >70 years)
Gastrointestinal Cancers
Colon Cancer
-
-
A
PRELIMINARY SCORE
DFS
ADJUSTMENTS
FINAL SCORE
F1
A
5-FU/LV (fluorouracil + leucovorin) or 5-FU/LEV (fluorouracil + levamisole)
-
Surgery alone (Pooled-analysis)
Patients with stage II and III colon cancer
Gastrointestinal Cancers
Colon Cancer
-
-
A
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F1
A
5-FU/LV (fluorouracil + leucovorin) or 5-FU/LEV (fluorouracil + levamisole)
-
Surgery alone (Meta-analysis)
Patients with resected stage II and III colon cancer
Gastrointestinal Cancers
Colon Cancer
-
-
A
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F1
A
5-FU/LV (fluorouracil + leucovorin) or 5-FU/LEV (fluorouracil + levamisole)
-
Surgery alone (Meta-analysis)
Patients with resected stage II and III colon cancer
Gastrointestinal Cancers
Colon Cancer
-
-
A
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F1
A
5FU/LEV (5-fluorouracil + levamisole)
-
Levamisole
Resected stage III (Dukes stage C) colon cancerIntergroup 0035
Gastrointestinal Cancers
Colon Cancer
-
Intergroup 0035
A
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F1
A
Tivozanib
-
Sorafenib
Adult patients with relapsed or refractory advanced RCC following ≥2 prior systemic therapies TIVO-3
Genitourinary Cancers
Renal cell cancer
-
TIVO-3
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
3
Enzalutamide
ADT (androgen deprivation therapy)
Placebo + ADT
For the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapyARCHES
Genitourinary Cancers
Prostate cancer
-
ARCHES
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Lorlatinib
-
Crizotinib
Treatment of adult patients with anaplastic lymphoma kinase (ALK) positive (NSCLC) previously not treated with an ALK inhibitor CROWN
Thoracic Malignancies
Non-small-cell Lung Cancer
ALK+
CROWN
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Sacituzumab govitecan-hziy
-
Physician’s choice of single agent ChT
Treatment of patients with unresectable or metastatic TNBC who have received ≥2 prior systemic therapies, ≥1 of them for advanced disease ASCENT
Breast Cancer
Breast Cancer
Triple-negative
ASCENT
5
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
5
Nivolumab
Cabozantinib
Sunitinib
First-line treatment of adult patients with advanced RCCCheckMate-9ER
Genitourinary Cancers
Renal cell cancer
-
CheckMate-9ER
1
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
1
Atezolizumab
-
Single arm (Phase II)
Single-arm study of atezolizumab in patients with locally advanced or metastatic urothelial bladder cancerIMvigor210 (Cohort 2)
Genitourinary Cancers
Urothelial Carcinoma
-
IMvigor210 (Cohort 2)
1
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
1
Enfortumab vedotin
-
Single arm (Phase II)
Patients with locally advanced or metastatic UC who are ineligible for cisplatin-containing ChT and have previously received ≥1 prior lines of therapy EV-201 - Cohort 2
Genitourinary Cancers
Urothelial Carcinoma
-
EV-201 - Cohort 2
3
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
3
Erdafitinib
-
Single arm (Phase II)
Locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 or FGFR2 genetic alterations and disease progression during/after ≥1 prior platinum-containing ChTBLC2001
Genitourinary Cancers
Urothelial Carcinoma
FGFR3 or FGFR2 genetic alterations
BLC2001
1
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
1
Pembrolizumab
-
Single arm
Locally advanced or metastatic UC in adults who are not eligible for cisplatin-containing ChT and whose tumours express PD-L1 with a CPS ≥10KEYNOTE-052
Genitourinary Cancers
Urothelial Carcinoma
PD-L1 CPS ≥10%
KEYNOTE-052
3
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
3
Pembrolizumab
-
Investigator’s choice of ChT (paclitaxel, docetaxel or vinflunine)
Locally advanced or metastatic UC in adults who have received prior platinum-containing ChTKEYNOTE-045
Genitourinary Cancers
Urothelial Carcinoma
-
KEYNOTE-045
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Nivolumab
-
Placebo
Adjuvant therapy for adult patients with oesophageal or gastroesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy CheckMate 577
Gastrointestinal Cancers
Oesophageal or gastroesophageal carcinoma
-
CheckMate 577
A
PRELIMINARY SCORE
DFS
ADJUSTMENTS
FINAL SCORE
F1
A
Sotorasib
-
Single arm
Treatment of adults with advanced non-small cell lung cancer with KRAS G12C mutation and who have progressed after at least one prior line of systemic therapy CodeBreaK 100
Thoracic Malignancies
Non-small-cell Lung Cancer
KRAS G12C mutated
CodeBreaK 100
3
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
3
Cemiplimab
-
Single arm (Phase II)
Treatment of basal cell carcinoma (laBCC or mBCC) who have progressed on or are intolerant to a hedgehog pathway inhibitor (HHI) Study 1620
Skin Cancers
Basal Cell Carcinoma
-
Study 1620
3
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
3
Nivo/Ipi (nivolumab and ipilimumab)
-
Single arm (Phase II)
Treatment of adult patients with dMMR or MSI-H mCRC after prior fluoropyrimidine-based combination ChT CheckMate142
Gastrointestinal Cancers
Colorectal Cancer
dMMR or MSI-H
CheckMate142
3
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
3
Pemetrexed
Cisplatin
Cisplatin
In combination with cisplatin for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesotheliomaEMPHACIS
Thoracic Malignancies
Pleural mesothelioma
-
EMPHACIS
3
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
3
Lenvatinib
Pembrolizumab
Sunitinib
Treatment of adults with advanced renal cell carcinoma in combination with pembrolizumab as first-line treatmentCLEAR
Genitourinary Cancers
Renal cell cancer
-
CLEAR
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Pembrolizumab
ChT (paclitaxel + carboplatin)
Placebo plus ChT (paclitaxel + carboplatin)
In combination with ChT as neoadjuvant treatment and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced, or early‑stage triple‑negative breast cancer at high risk of recurrenceKEYNOTE-522
Breast Cancer
Early Breast Cancer
Triple-negative
KEYNOTE-522
A
PRELIMINARY SCORE
DFS
ADJUSTMENTS
FINAL SCORE
F1
A
Enfortumab vedotin
-
Investigator-chosen ChT (standard docetaxel, paclitaxel or vinflunine)
Treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor-1 or programmed death-ligand 1 inhibitorEV-301
Genitourinary Cancers
Urothelial Carcinoma
-
EV-301
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Pembrolizumab
-
Single arm (Phase II)
Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomyKEYNOTE-057
Genitourinary Cancers
Urothelial Carcinoma
-
KEYNOTE-057
3
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
3
Nivolumab
Fluoropyrimidine and platinum ChT (FOLFOX or CAPOX)
ChT (FOLFOX or CAPOX)
First-line treatment for patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer and oesophageal adenocarcinoma CheckMate 649
Gastrointestinal Cancers
Gastric or gastroesophageal junction cancer and oesophageal adenocarcinoma
-
CheckMate 649
1
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
1
Nivolumab
Fluoropyrimidine and platinum ChT (FOLFOX or CAPOX)
ChT (FOLFOX or CAPOX)
First‑line treatment for patients with HER2‑negative advanced or metastatic gastric, gastroesophageal junction or oesophageal adenocarcinoma whose tumours express PD-L1 with a CPS ≥5CheckMate 649
Gastrointestinal Cancers
Gastric or gastroesophageal junction cancer and oesophageal adenocarcinoma
HER2- PD-L1 CPS ≥5
CheckMate 649
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Pralsetinib
-
Single arm
Treatment for adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA-approved testARROW
Thoracic Malignancies
Non-small-cell Lung Cancer
RET fusion-positive
ARROW
3
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
3
Pralsetinib
-
Single arm
Treatment for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitorARROW
Breast Cancer
Non-small-cell Lung Cancer
RET fusion-positive
ARROW
3
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
3
Watchlist
Tested Agent(s)
Combined Agent(s)
Control Arm
Therapeutic Indication
Tumour Type
Tumour Sub-type
Tumour Sub-group
Trial Name
Ref.
Score
Scorecard
Scorecard
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.